chemieunternehmen.com

Evotec SE today announced that the Company has entered into a multi-RNA target alliance with Takeda Pharmaceutical Company Limited (“Takeda”) with the goal to discover and develop RNA targeting small molecule therapeutics for highly attractive targets that are difficult to address via more conventional approaches. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-takeda-enter-strategic-rna-targeting-drug-discovery-and-development-alliance-6038

Evotec announces that the Company has been selected as a winner of a 2021 CMO Leadership Award in the categories Compatibility (Big Pharma), Expertise (Big Pharma), and Service (Overall, Small Pharma) Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/cmo-leadership-awards-2021-6036

Evotec SE will announce its financial results for 2020 on Thursday, 25 March 2021. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-se-to-announce-results-for-fiscal-year-2020-on-25-march-2021-6034

Just – Evotec Biologics’ Redmond, Washington site offers true meaning to “Facility of the Future” with flexible and podular manufacturing of clinical and commercial-stage biologics. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/g-con-manufacturing-and-just—evotec-biologics-complete-the-installation-of-cleanroom-podsr-for-the-first-jpodr-facility-in-north-america-6032

Argobio SAS, a newly-created start-up studio dedicated to life sciences, today announced its launch with 50 M€ of committed capital. Argobio was initiated by Kurma Partners, a leading Paris and Munich-based healthcare venture capital firm, and Bpifrance, the French national investment bank. Kurma and Bpifrance were joined by complementary strategic investors, Angelini Pharma, a private international pharmaceutical company, Evotec, a drug discovery alliance and development partnership company, and the Institut Pasteur, internationally renowned center for biomedical research.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/argobio-announces-its-launch-with-50-meur-to-create-and-develop-pioneering-biotech-spinouts-with-the-support-of-bpifrance-kurma-partners-angelini-pharma-evotec-and-the-institut-pasteur-6030

Evotec SE and Chinook Therapeutics, Inc. today announced a strategic collaboration focused on the discovery and development of novel precision medicine therapies for patients with chronic kidney diseases (“CKD”). Based on Evotec’s proprietary comprehensive molecular datasets from thousands of patients across chronic kidney diseases of multiple underlying etiologies, Chinook and Evotec will jointly identify, characterise and validate novel mechanisms and discover and develop precision medicines.  Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-chinook-therapeutics-enter-into-strategic-collaboration-to-discover-and-develop-novel-precision-medicines-for-chronic-kidney-diseases-6028